1. Signaling Pathways
  2. Apoptosis
  3. Bcl-2 Family

Bcl-2 Family

Bcl-2 is a family of evolutionarily related proteins. These proteins govern mitochondrial outer membrane permeabilization (MOMP) and can be either pro-apoptotic (Bax, Bad, Bak and Bok among others) or anti-apoptotic (including Bcl-2 proper, Bcl-xL, and Bcl-w, among an assortment of others). There are a total of 25 genes in the Bcl-2 family known to date. Human genes encoding proteins that belong to this family include: Bak1, Bax, Bal-2, Bok, Mcl-1.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147929
    Apoptotic agent-3
    Activator
    Apoptotic agent-3 (compound 15f) promotes apoptosis through the potential mitochondria-mediated Bcl-2/Bax pathway and activation of the Caspase 3 pathway. Apoptotic agent-3 exhibits anti-proliferative activities and can be used for cancer research.
    Apoptotic agent-3
  • HY-P5325
    Bid BH3 (80-99)
    Bid BH3 (80-99) is a biological active peptide. (BID is a pro-apoptotic member of the 'BH3-only' (BOPS) subset of the BCL-2 family of proteins that constitute a critical control point in apoptosis. Bid is the first of the BOPs reported to bind and activate Bcl-2, Bax, and Bak. Bid serves as a death-inducing ligand that moves from the cytosol to the mitochondrial membrane to inactivate Bcl-2 or to activate Bax.Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)
    Bid BH3 (80-99)
  • HY-P10386
    155H1
    Inhibitor
    155H1 (Compound 11) is a stapled peptide, that covalently binds hMcl1 (172-323) with IC50 of 18 nM.
    155H1
  • HY-RS01428
    Bcl2l11 Mouse Pre-designed siRNA Set A
    Inhibitor

    Bcl2l11 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bcl2l11 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Bcl2l11 Mouse Pre-designed siRNA Set A
    Bcl2l11 Mouse Pre-designed siRNA Set A
  • HY-RS01419
    Bcl2a1 Rat Pre-designed siRNA Set A
    Inhibitor

    Bcl2a1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bcl2a1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Bcl2a1 Rat Pre-designed siRNA Set A
    Bcl2a1 Rat Pre-designed siRNA Set A
  • HY-168623
    EGFR-IN-134
    Inhibitor
    EGFR-IN-134 (compound 3f), a triazolo[3,4-a]isoquinoline derivative, is a potent EGFR inhibitor with an IC50 of 0.023 µM. EGFR-IN-134 induces apoptosis and necrosis. EGFR-IN-134 initiates cell cycle arrest at the G2/M and pre-G1 phases, downregulates anti-apoptotic protein Bcl2 and upregulates pro-apoptotic proteins: p53, Bax, and caspases 3, 8, and 9. EGFR-IN-134 shows antiproliferative and anticancer activity.
    EGFR-IN-134
  • HY-153494
    Rosomidnar
    Inhibitor
    PNT100 is a 24-base, chemically unmodified DNA oligonucleotide sequence that is complementary to the regulatory region upstream of the BCL-2 gene. Exposure of tumor cells to PNT100 results in suppression of proliferation and cell death.
    Rosomidnar
  • HY-169172
    Bfl-1-IN-5
    Inhibitor
    Bfl-1-IN-5 (Compound (R,R,S)-26) is a selective inhibitor for Bfl-1 with an IC50 of 0.022 μM. Bfl-1-IN-5 promotes the caspase-3/7 activity with an EC50 of 0.37 μM, and inhibits the cell viability of SU-DHL-1 with an EC50 of 1.3 μM.
    Bfl-1-IN-5
  • HY-RS01434
    BCL2L2 Human Pre-designed siRNA Set A
    Inhibitor

    BCL2L2 Human Pre-designed siRNA Set A contains three designed siRNAs for BCL2L2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    BCL2L2 Human Pre-designed siRNA Set A
    BCL2L2 Human Pre-designed siRNA Set A
  • HY-153594
    Bcl-B inhibitor 1
    Inhibitor ≥98.0%
    Bcl-B inhibitor 1 is a Bcl-B inhibitor.
    Bcl-B inhibitor 1
  • HY-170763
    Mcl-1 inhibitor 22
    Mcl-1 inhibitor 22 (Example 36) is a myeloid cell leukemia-1 (MCL-1) inhibitor which inhibits the antiapoptotoic activity of MCL-1 by inhibiting its interaction with proapototic proteins. Mcl-1 inhibitor 22 exhibits anti-proliferation activities against various cancer cell lines and can be utilized in cancer research.
    Mcl-1 inhibitor 22
  • HY-RS01435
    Bcl2l2 Mouse Pre-designed siRNA Set A
    Inhibitor

    Bcl2l2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bcl2l2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Bcl2l2 Mouse Pre-designed siRNA Set A
    Bcl2l2 Mouse Pre-designed siRNA Set A
  • HY-125191
    BRD1991
    Inhibitor
    BRD1991 selectively disrupts Beclin 1/Bcl-2 binding and induces autophagy without triggering apoptosis or other forms of cell death.
    BRD1991
  • HY-113427S
    trans-Vaccenic acid-d13
    Inhibitor
    trans-Vaccenic acid-d13 is deuterium labeled trans-Vaccenic acid (HY-113427). trans-Vaccenic acid is a naturally occurring trans fatty acid (TFA). trans-Vaccenic acid inhibits nasopharyngeal carcinoma (NPC) cell growth and induces apoptosis through the inhibition of Bad/Akt phosphorylation. trans-Vaccenic acid is a precursor for the synthesis of saturated fatty acid in the rumen and of conjugated Linoleic acid (CLA) at the tissue level. trans-Vaccenic acid exerts hypolipidemic effects in a rat model of obesity.
    trans-Vaccenic acid-d<sub>13</sub>
  • HY-123244
    YC137
    Antagonist
    YC137 is a potent Bcl-2 antagonist with Kis of 1.3 μM and >100 μM for Bcl-2 and Bcl-xL when assayed in Bis-Tris buffer, respectively. YC137 inhibits the binding of the Bid BH3 peptide to Bcl-2, thus disrupting an interaction essential for the antiapoptotic activity of Bcl-2. YC137 selectively induces apoptosis of Bcl-2-dependent cells. YC137 has the potential for breast cancer research.
    YC137
  • HY-B1971R
    Deltamethrin (Standard)
    Deltamethrin (Standard) is the analytical standard of Deltamethrin. This product is intended for research and analytical applications. Deltamethrin (Decamethrin) is an orally active synthetic pyrethroid insecticide. Deltamethrin induces oxidative stress and results in inflammation and apoptosis via inhibiting Nrf2/HO-1 pathway. Deltamethrin has an anticancer effect by inducing apoptosis. Deltamethrin can be used extensively in pest control.
    Deltamethrin (Standard)
  • HY-101999
    EM20-25
    Inhibitor
    EM20-25 is an inhibitor for Bcl-2, which interferes with the interaction between BCL-2 and BAX, activates caspase-9 and thus induces the apoptosis. EM20-25 affects the mitochondrial function, causes the open of permeability transition pore (PTP). EM20-25 enhances the sensitivity of cells to Staurosporine (HY-15141), and enhances the killing effect of BCL-2-expressing leukemia cells to Chlorambucil (HY-13593) and Fludarabine (HY-B0069).
    EM20-25
  • HY-170762B
    (-)-Mcl-1 inhibitor 21
    (-)-Mcl-1 inhibitor 21 (Example 1-38) is a Mcl-1 inhibitor with an IC50 of 7.51 μM. (-)-Mcl-1 inhibitor 21 exhibits proapototic and anti-proliferation activities against SUDHL5 and SUDHL10 cell lines and can be utilized in cancer research.
    (-)-Mcl-1 inhibitor 21
  • HY-129325
    Cytochalasin H
    Inhibitor
    Cytochalasin H is a nature product that could be isolated from fungus Phomopsis sp. Cytochalasin H inhibits cell growth and induces apoptosis. Cytochalasin H has anti-angiogenic activity. Cytochalasin H is an antibiotic and has antibacterial activity.
    Cytochalasin H
  • HY-172551
    anti-TNBC agent-9
    Inhibitor
    anti-TNBC agent-9 (Compound 3as) is an anti-cancer agent for triple-negative breast cancer (TNBC). anti-TNBC agent-9 exhibits significant inhibitory activity against MDA-MB-453 cells with an IC50 value of 8.5 μM. anti-TNBC agent-9 inhibits tumor cell migration by upregulating E-cadherin and downregulating N-cadherin, matrix metalloproteinase 2 (MMP2), and MMP9. anti-TNBC agent-9 induces apoptosis by increasing the expression of the pro-apoptotic protein BAX and decreasing the expression of the anti-apoptotic protein BCL-2, thereby inhibiting tumor cell proliferation.
    anti-TNBC agent-9
Cat. No. Product Name / Synonyms Application Reactivity

Bcl-2 family members have been grouped into three classes. The anti-apoptotic subfamily contains the Bcl-2, Bcl-XL, Bcl-w, Mcl-1, Bfl1/A-1, and Bcl-B proteins, which suppress apoptosis and contain all four Bcl-2 homology domains, designated BH1-4. The pro-apoptotic subfamily contain BH1-3 domains, such as Bax, Bak, and Bok. A third class of BH3 only proteins Bad, Bid, Bim, Noxa and Puma have a conserved BH3 domain that can bind and regulate the anti-apoptotic BCL-2 proteins to promote apoptosis [1].


The intrinsic pathway is initiated by various signals, principally extracellular stimuli. BH3-only proteins (Bim, Bid, Bad, Noxa, Puma) engage with anti-apoptotic Bcl-2 family proteins to relieve their inhibition of Bax and Bak to activate them. Next, Bax and Bak are oligomerized and activated, leading to mitochondrial outer membrane permeabilization. Once mitochondrial membranes are permeabilized, cytochrome c and/or Smac/DIABLO is released into the cytoplasm, wherein they combine with an adaptor molecule, Apaf-1, and an inactive initiator Caspase, Pro-caspase 9, within a multiprotein complex called the apoptosome. Smac/DIABLO inhibits IAPs to activate Caspase 9. Caspase 9 activates Caspase 3, which is the initiation step for the cascade of Caspase activation. The extrinsic pathway can be activated by cell surface receptors, such as Fas and TNF Receptor, subsequently activating Caspase 8, and leads to Caspase 3 activation and cell demolition. Caspases in turn cleave a series of substrates, activate DNases and orchestrate the demolition of the cell. Bcl-2 family proteins are also found on the endoplasmic reticulum and the perinuclear membrane in hematopoietic cells, but they are predominantly localized to mitochondria [2]

 

Reference:
[1]. Cotter TG, et al. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. 2009 Jul;9(7):501-7.

[2]. Kang MH, et al. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009 Feb 15;15(4):1126-32.

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.